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Diagnosis of equine herpesvirus-1 associated myeloencephalopathy (EHM) can be troublesome, but 
early recognition and knowledge of risk factors are essential for prevention and control. The 
objectives for this study are to 1) describe EHM in France, 2) improve clinical recognition, 3) 
identify risk factors. Through epidemiosurveillance of acute neurological cases (all considered 
to be potentially infectious cases) in France (2008-2011), 26 EHM cases were identified and 29 
EHM negative control cases. EHM cases were described and compared to controls with univariate, 
multivariate and classification and regression tree analysis. EHM cases had a 46% fatality rate and 
were frequently isolated cases. Most showed ataxia, paresis and a cauda equina syndrome, yet 
presence of other neurological signs was variable. Statistical analysis identified the following 
variables to be significantly associated to EHM compared to controls: introduction of a new horse 
to the herd, cauda equina syndrome, larger herd size, saddle horses and month of occurrence. The 
presence of many isolated cases, and less typical and variable clinical presentations emphasize the 
difficulty in diagnosing EHM. Nevertheless, history and clinical examination of acute neurological 
cases can be valuable in recognizing EHM early as well in order to select those cases that need 
further laboratory testing and infection control measures. Moreover, with a different study format 
and geographic location, risk factors were found to be similar to previous studies, therefore 
strengthening their significance to the spread of EHM. 
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Introduction 
Neurological disorders caused by equine herpesvirus-1 (EHV-1) are called equine herpesvirus-1 
associated myeloencephalopathy (EHM) and this is considered a contagious emerging syndrome 
(Lunn et al., 2009; Kydd et al., 2010; Traub-Dargatz et al., 2013). Currently, early recognition of 
suspected cases and close monitoring of high-risk horses represent the most reliable measures for 
preventing EHM outbreaks and limiting the consequences (Lunn et al., 2009; Pusterla et al., 2009). 
Although clinical signs of EHM are often perceived as well described (Kydd et al., 2010) and 
clinical diagnosis therefore straightforward, its clinical recognition can be troublesome, especially 
when isolated cases are considered rather than outbreaks. The diffuse and multifocal distribution of 
the lesions in the central nervous system (Lunn et al., 2009; Pusterla et al., 2009) can cause 
considerable variability in clinical presentation (van der Meulen et al., 2003; Pusterla et al., 2009). 
Laboratory analyses therefore remain indispensable, but take up precious time. New tools for 
improved clinical recognition of EHM would therefore be highly valuable. 
Geographical region appears to be associated with EHM development (Goehring et al., 
2006; Lunn et al., 2009) and risk factors could therefore potentially differ between countries. There 
are only few reports available in literature on EHM in France (Pronost et al., 2010b; Pronost et al., 
2012) and none describe risk factors.  Moreover, epidemiological studies are often restricted to a 
single outbreak, thereby limiting their potential at identifying risk factors unrelated to a specific 
outbreak. More data establishing possible risk factors are required (Lunn et al., 2009).  
This study aims at improving the current understanding of EHM by: 1) describing EHM in 
France, 2) improving early clinical recognition of EHM by identifying variables that are 
specifically related to EHM rather than to other equine acute neurological diseases, and 3) the 




In France, a passive epidemiological surveillance program is implemented by the “Réseau 
d’Epidémio-Surveillance en Pathologie Equine” (RESPE; http://www.respe.net) to detect and 
monitor emerging and infectious neurological equine diseases, one of which is EHM. Veterinarians 
throughout France are asked to report all horses with acute neurological signs (all are considered 
potentially infectious), and to fill in a detailed standardized questionnaire for each case. Laboratory 
analysis was offered free of charge. There is owner informed consent. 
 
Retrieved data from reported cases and definitions 
Detailed information on season, and demographic, management, clinical and laboratory data were 
retrieved from the reporting veterinarians with use of standardized questionnaires. Cauda equina 
syndrome was defined as presence of a single or a combination of clinical signs related to 
lumbosacral cord pathology, i.e. an abnormal tonus, reflexes and sensibility of tail, anus and/or 
perineum, inability to urinate and/or defecate and urinary incontinence. Urinary retention caused by 
upper motor neuron lesions was also included in this definition, as reflection of diagnostic 
difficulties under field conditions.  
 
EHM cases 
Reported cases with acute neurological signs (regardless of further clinical and specific 
neurological signs) and with a positive test result for EHV-1 were considered EHM cases. EHV-1 
positive testing was based on recent reviews (Lunn et al., 2009; Pusterla et al., 2009): 1) for ante 
mortem testing, a positive polymerase chain reaction (PCR) on nasal swabs, blood and / or 
cerebrospinal fluid, 2) for post mortem testing, histology with characteristic lesions in the spinal 
cord (vasculitis), or positive PCR from nervous tissue, or 3) seroconversion for EHV on acute and 
convalescent serum (4-fold increase)..  
 
Control cases 
The control group included reported cases that: 1) presented with acute neurological signs, and 
therefore were clinically suspect to have infectious neurological diseases amongst which EHM, and 
2) were considered not to be infected with EHV-1 following diagnostic laboratory testing. They 
were considered EHV negative based on: 1) absence of seroconversion for EHV on paired sera or 
on a single serum taken > 1 week after disease onset, and/or 2) negative PCR (control cases should 
not have a positive PCR, but a negative PCR test was considered inadequate to rule out EHM) 
and/or 3) confirmation or high suspicion of another disease leading to neurological signs. To reduce 
bias as much as possible, the latter criterium was minimally based on clinical signs and mainly 
based on additional diagnostic testing. 
 
Laboratory testing 
Depending on the samples sent by the reporting veterinarian, complement fixation testing on blood 
and real-time PCR (on blood, cerebrospinal fluid, nasal swab and/or tissue) were performed as 
previously described (Pronost et al., 2012; Slater, 2014). 
 
Statistical methods 
To compare the EHM cases versus control cases, frequency variables were assessed by odds ratio 
(OR), categorical variables were assessed by Fisher’s exact test and quantitative variables were 
assessed by a two-sample Wilcoxon rank-sum test. All variables with a P-value < 0.10 in those 
univariate analyses were entered in a multivariate logistic regression. In addition, to assess 
collinearity, a backward elimination of variables was performed. Variables that induced a 
modification of OR of >20% were retained in final analysis. Goodness of fit was assessed using the 
Hosmer–Lemeshow goodness-of-fit test (StataCorp, 2012). Furthermore, classification and 
regression tree (CART) analysis (Saegerman et al., 2011) were performed to compare history and 
clinical signs or only clinical signs between groups.  
Results 
Description 
Out of the 219 neurological cases reported to the RESPE from 2008 to 2011, 26 cases fulfilled the 
inclusion criteria for EHM cases, and 29 for control cases. All EHM cases were considered EHV 
positive based on a positive PCR for EHV-1 on blood, nasal swab, cerebrospinal fluid and/or 
nervous tissue. The two cases that underwent a full post-mortem examination furthermore showed 
typical histology following post-mortem. Table 1 and 2 summarize signalment and history. EHM 
cases were Selle Francais (8), Thoroughbreds (4), Arabian horses (3), Spanish breed (1), French 
trotter (1), barb horse (1), poney (1), welsh (1), KWPN (1), Quarter Horse (1), unspecified saddle 
horse breeds (4). Three EHM cases were diagnosed in 2008, 7 in 2009, 11 in 2010 and 5 in 2011, 
and most (17) during winter months. No significant seasonal difference was observed between 
groups (P = 0.47). Some cases occurred together in the same herd or were related to each other, but 
half of them were unrelated to other cases (13/26). Clinical signs and their comparison between 
groups are described in Table 3, and details on neurological signs of EHM cases in Table 4. Apart 
from the fact that most EHM cases showed ataxia or paresis and a cauda equina syndrome, the 
remainder of the clinical picture was found to be variable. The mortality rate of the EHM group was 
46%. 
Control horses (29) were considered to be EHM negative based on absent seroconversion on 
paired sera (13), low antibody titre on a single serum taken > 1 week after the onset of clinical signs 
(2), and/or confirmation or high suspicion of another disease (17; Table 5).  
 
Statistical analysis 
Introduction of a new horse to the herd, EHV vaccination (but not if EHV vaccination occurred less 
than 6 months ago), and cauda equina syndrome were variables with a significantly higher 
association to EHM horses than controls. The herd size was significantly larger for EHM than for 
controls (Table 2 and 3). On the multivariate analysis only the introduction of a new horse to the 
herd (OR = 14.64; 95% CI: 1.32-161.93; P = 0.03) and cauda equina syndrome (OR = 28.49; 95% 
CI: 1.23-427.07; P = 0.015) could be retained. The CART analysis showed that when variables of 
history and the clinical exam were used, herd size, month of occurrence and introduction of a new 
horse in the herd were the best predictors for EHM, and this with a sensitivity of 65% and 
specificity of 52% for the decision tree. When only the clinical exam was taken in consideration, 




This study provides clinical and epidemiological data on French EHM cases over a period of 4 
years. The number of French EHM cases is believed underestimated, because of underreporting of 
this unnotifiable disease and the associated diagnostic challenges. From these results, it can be 
suggested that EHM occurs in the form of isolated cases at least as often as in the form of an 
outbreak, highlighting the need for improved tools for clinical recognition. Besides the fact that 
most EHM cases showed ataxia and/or paresis and a cauda equina syndrome, the clinical picture of 
EHM in the reported cases was variable. Some cases were reported with cerebral signs of abnormal 
behaviour; this is not the most typical expression of EHM, nevertheless it has been previously 
described (van der Meulen et al., 2003). This highly variable clinical picture, the atypical 
neurological expressions and the high number of isolated cases are all likely to be a result of the 
surveillance format used, where all acute neurological cases were considered as potentially 
infectious, reported and tested, therefore including EHM cases that might otherwise remain 
unidentified.   
Not unexpectedly, cauda equina syndrome was the only clinical variable significantly more 
present in EHM horses than in controls. The definition of cauda equina syndrome in this study was 
rather large, including urinary retention due to both lower motor neuron and upper motor neuron 
lesions. While probably better reflecting the field conditions, this leads to an overestimation of 
control cases with a cauda equina syndrome and therefore underestimation of its statistical power 
and specificity as a predictor for EHM. Nonetheless, its odds ratios are still high. Following the 
results of this study, it is 28 times more likely that a veterinarian is dealing with EHM than another 
neurological disease when he or she is called to see a horse with acute neurological symptoms and 
identifies a cauda equina syndrome. Also in the CART analysis, cauda equina syndrome was 
considered a main predictor for EHM and showed a good sensitivity. This makes it potentially a 
very useful clinical indicator as a first screening tool for syndromic surveillance for EHM. Of 
course after clinical suspicion, laboratory analysis remains necessary.  
Age and sex were not statistically different between groups in the current study but it should 
be noted that, similar to studies performed in The Netherlands (Goehring et al., 2006), and in the 
USA (Henninger et al., 2007) EHM was not associated with young age. Nonetheless, EHM has 
been reported in horses of all ages (Greenwood and Simson, 1980; Friday et al., 2000). Breed was 
different between groups in the present study, with more saddle horses in the EHM group. Breed 
has been previously identified to be a risk factor for EHM (Goehring et al., 2006; Barbic et al., 
2012), with Haflingers, Fjord horses, Icelandic horses and archetypical pony breeds less frequently 
affected by EHM (Goehring et al., 2006).  
Introduction of horses to a herd before development of EHM outbreaks is commonly 
reported (van Maanen et al., 2001; van der Meulen et al., 2003; Goehring et al., 2006; Henninger et 
al., 2007), and was identified as a risk factor for EHM in this study by all different statistical means. 
Following our results, it is 14-15 times more likely to be EHM than another neurological disease 
when this variable is present in the history of an acute neurological case.  
EHV vaccination was not uncommon in all groups and the findings of this study cannot 
support it to be a risk factor for EHM. Although by univariate analysis EHV vaccination was 
identified as a risk factor, it could not be retained in the multivariate analysis and more importantly 
failed as a risk factor in the univariate analysis when only those horses were taken into account 
where EHV vaccination was performed within the last 6 months before EHM developed. EHV 
vaccination was reported previously to be associated with EHM (Henninger et al., 2007; Traub-
Dargatz et al., 2013), but EHM also develops in populations where none or few horses are 
vaccinated (Goehring et al., 2006) and vaccination status could have been potentially confounded 
with increasing age (Lunn et al., 2009). The current study shows that age is unlikely to be a 
confounding factor since vaccinated EHM cases were younger than those unvaccinated (12.0 ± 4.2 
versus 14.6 ± 3.6 years, respectively).  
In this study, the variables significantly different between groups have been identified by 
statistical comparison of EHM cases to a control group. Both groups potentially have infectious 
neurological diseases due to the presence of acute neurological signs, and therefore those variables 
have diagnostic potential. At the same time the significantly different variables between groups can 
be appreciated as risk or protective factors for attracting EHM compared to another acute 
neurological disease. This type of control group has not been used previously for risk analysis of 
EHM.  
Limitations include the retrospective nature of this work, the relatively limited case numbers 
and reporting by different veterinarians mostly under field conditions. However, potential bias has 
been reduced to a minimum by the use of a structured network, standardized clinical forms and case 
classification by an expert committee.  
 
Conclusion 
This study is the first to provide a thorough description of French EHM cases, including outbreaks 
and a high percentage of isolated cases. Although the clinical picture can be variable, the history 
and clinical examination of acutely neurologically affected horses can potentially be a valuable help 
to recognize EHM cases early, and to select those cases that would need further laboratory testing 
and immediate infection control measures. In addition, risk factors for EHM were identified and 
although in a different geographic location and study setup they were largely in accordance with 
other studies, therefore strengthening their significance in the spread of EHM.  
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Table 1. Signalment of horses with equine herpesvirus-1 associated myeloencephalopathy (EHM) 
and herpes virus negative control groups, and univariate statistical comparison between EHM and 
control groups. 
 
 EHM cases (26) Control cases 
(29) 
EHM vs controls 
   P value  
Age (years) 
median ± SD 
range 
n 
14.0 ± 4.5 
3-20 
25 




 N n % N n % P value  
Breed       0.06* 
 
Saddle horse 23 25 92 17 26 65 (saddle horses more frequent in EHM) 
 
Pony  2 25 8 8 26 31  
 
Draft horse 0 25 0 0 26 0  
 
Donkey  0 25 0 1 26 4  
Sex       0.87 
 
Mare 14 22 64 15 29 52  
 
Stallion 5 25 20 5 29 17  
 




Legend: EHM = equine herpesvirus-1 associated myeloencephalopathy; SD = standard deviation; 
N = number of horses with a positive response; n = number of horses with a response for this 
specific parameter; * variable selected for multivariate analysis based on  
P < 0.10.
Table 2. History variables of horses with equine herpesvirus-1 associated myeloencephalopathy 















ciated myeloencephalopathy; SD = standard deviation; N = number of horses with a positive 
response; n = number of horses with a response for this specific parameter; OR = odds ratio; CI95% 
= confidence interval 95%;  
EHV = equine herpes virus; NU = not used for statistical comparison; * variable selected for 
multivariate analysis based on P < 0.10; # variable significantly different between groups.
 EHM cases  
(26) 
Control cases (29) EHM vs controls 
   P value  
Herd size (number of horses)  
median ± SD 
range 
n 
42.5 ± 33.7 
2-100 
22 




 N n % N n % P value 
Herd activity  1 
 Riding school  9 24 38 11 28 39  
 Training centre 0 24 0 1 28 4  
 Breeding facility 5 24 21 7 28 25  
 Pleasure riding / home 6 24 29 8 28 29  
   P value  OR CI95%xxx 
Vaccination status     
 EHV vaccinated 16 23 70 10 28 36 0.02*# 4.11 1.27-13.36 
 EHV vaccination < 6 months before disease 10 21 48 7 27 26 0.12 2.60 0.71-8.75 
 Tetanus vaccinated 21 22 95 21 28 75 0.08* 7.00 0.79-61.98 
Factors related to viral spread      
 Other sick horses since 3 months  13 20 65 10 26 38 0.16 2.31 0.72-7.38 
 New horse introduced in herd 14 20 70 5 24 21 0.002*# 8.87 2.25-35.00 
 Horse moved during last month 6 21 29 7 26 27 0.90 1.09 0.30-3.92 
Motif to call veterinarian (multiple answers possible)    
 Hyperthermia 4 20 20 2 26 8 0.23 2.77 0.49-18.36 
 Ataxia, paresis 10 20 50 7 26 27 0.11 2.71 0.79-9.31 
 Recumbence 5 20 25 2 26 8 NU NU NU 
 Lameness 0 20 0 3 26 12 NU NU NU 
 Other / aspecific neurological signs 3 20 15 9 26 35 NU NU NU 
 Other motif 2 20 10 7 26 27 NU NU NU 
Table 3. Clinical variables of horses with equine herpesvirus-1 associated myeloencephalopathy 
and control horses and univariate statistical comparison between groups. 
 
 EHM cases (26) Control cases 
(29) 
EHM vs controls 
   P value (Wilcoxon rank-sum 
test) 
Rectal temperature (°C) 
median ± SD 
range 
n 
38.7 ± 1.5 
35.0-40.8 
21 





 N n % N n % P value OR CI95%xxx 
Fever (>38.5°C) 11 21 52 7 21 33 0.22 2.20 0.63-7.66 
Respiratory signs 8 18 44 10 24 42 0.86 1.12 0.32-3.85 
Abnormal posture 5 21 24 4 23 17 0.60 1.48 0.34-6.48 
Recumbence  10 22 45 8 26 31 0.30 1.88 0.57-6.12 
Abnormal consciousness$ 7 16 44 15 25 60 0.25 0.50 0.15-1.62 
Abnormal behaviour$ 12 22 55 17 25 68 0.35 0.56 0.17-1.85 
Abnormal head position 2 18 11 3 24 13 0.89 0.88 0.13-5.87 
Cranial nerve affection$ 8 21 38 15 25 60 0.14 0.41 0.12-1.35 
Abnormalities cervical 
area 
11 19 58 21 26 81 0.10 0.33 0.09-1.27 
Ataxia / weakness$ 11 12 92 20 23 87 0.96 1.05 0,15-7.13 
Cauda equina syndrome$ 13 15 87 11 23 48 0.02*# 6.16 1.41-27.02 




Legend: EHM = equine herpesvirus-1 associated myeloencephalopathy; SD = standard deviation; 
N = number of horses with a positive response; n = number of horses with a response for this 
specific parameter; OR = odds ratio; CI95% = confidence interval 95%;  
EHV = equine herpesvirus; * variable selected for multivariate analysis based on  
P < 0.10; # variable significantly different between groups; $ see Table 4 for more details on this 
variable in EHM cases.
Table 4. Detailed description of neurological signs of horses with equine herpesvirus-1 associated 
myeloencephalopathy. 
 
Neurological signs EHM horses (26) 
  N n % 
Abnormal state of consciousness 7 16 44 
 Depression 6 16 38 
 Stupor  
 
1 16 6 
Abnormal behaviour 12 22 55 
 Aggression  1 21 5 
 Anxiety  4 21 19 
 Hyperesthesia  4 22 18 
 Convulsions  1 21 5 
 Head pressing 1 21 5 
 Circling  
 
1 21 5 
Cranial nerve affection* 8 21 38 
 Abnormal hearing 1 18 6 
 Abnormal Romberg’s test (blindfolding) 1 10 10 
 Abnormal menace response 3 15 20 
 Abnormal pupillary light reflex 3 16 19 
 Nystagmus and/or strabismus 3 15 20 
 Abnormal sensitivity of the face 4 16 25 
 Asymmetry and reduced mobility of the face due to facial paralysis 3 15 20 
 Abnormality in the masseter and/or jaw tonus 1 14 7 
 Sweating on the face 3 15 20 
 Abnormal vocalization 1 10 10 
 Abnormal swallowing 3 15 20 
 Abnormal tongue tonus 
 
2 13 15 
Ataxia / weakness 11 12 92 
 All four limbs in a similar grade 5 12 42 
 More severe in the hind limbs than in the front limbs 3 12 25 
 Only in the hind limbs 
 
2 12 17 
Cauda equina syndrome* 13 15 87 
 Urinary incontinence 2 16 13 
 Urinary retention 12 19 63 
 Abnormal tail and/or anal tonus 9 15 60 
 Abnormal perineal reflex 6 15 40 




Legend: EHM = equine herpesvirus-1 associated myeloencephalopathy;  
N = number of horses with a positive response; n = number of horses with a response for this 
specific parameter; * horses showed different combinations.
Table 5. Diseases diagnosed in horses from the equine herpes virus negative control group. 
 
Diagnosis  Number of horses from control 
group 
Horses where a diagnosis or a very high suspicion was 
reached * 
17 
 Equine motor neuron disease (EMND) 5 
 Hepatoencephalopathy 2 
 Cervical spinal cord compression 3 
 Hyperkalemic periodic paralysis (HYPP) 1 
 Tetanus 1 
 Borna virus myeloencephalopathy 1 
 Bacterial encephalomyelitis 1 
 Fungal encephalomyelitis 1 
 Cranial nerve affection due to guttural pouch empyema 1 
 Spinal melanoma 
 
1 
Horses without definitive diagnosis but negative for equine 
herpes virus 
13 
 Highly suspected to have cervical compression or 
(encephalo-) myelitis 
4 
 Highly suspected to have a brain lesion or (myelo-) 
encephalitis 
7 
 Uncertain origin of single cranial nerve dysfunction 
 
1 




Legend: * in addition to the fact that another neurological disease was diagnosed, some of these 
horses were also tested negative for equine herpes virus. 
 
 
 
 
